Reno, Nevada (UroToday.com) -- AVEO Oncology, an LG Chem company (“AVEO”), announced their late-breaking abstract detailing their Phase 3 TiNivo-2 trial has been selected as a Proffered Paper oral presentation at the 2024 European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain this September 13-17th.
The oral presentation will announce the results from the TiNivo-2 clinical trial, which was designed to evaluate the benefit of adding nivolumab, a PD-1 checkpoint inhibitor, to low dose (0.89mg) FOTIVDA® (tivozanib), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) versus standard dose (1.34mg) FOTIVDA in the second-line following immune checkpoint inhibitor (ICI) combinations or the third-line setting following prior ICI treatment. Details of the presentation are as follows:
| Title: | Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in Patients With Metastatic Renal Cell Carcinoma Following an Immune Checkpoint Inhibitor: Results of the Phase 3 TiNivo-2 Study |
| Speaker: | Toni Choueiri, MD, Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute, Boston, MA, United States of America |
| Presentation #: | LBA73 |
| Category: | Proffered Paper session 1: GU tumors, non-prostate |
| Date & Time: | Friday, September 13, 2024; 2:00 – 2:10 pm CET |
TiNivo-2 Clinical Trial Details
Phase 3 clinical trial designed to evaluate the safety and efficacy of tivozanib in combination with nivolumab, as compared to tivozanib as a monotherapy, in RCC patients whose tumors progressed following prior ICI therapy.
Source: AVEO Oncology. (2024). AVEO Oncology, an LG Chem company, Announces Acceptance of Late-Breaking Oral Presentation of TiNivo-2 Results at ESMO 2024 [Press release]. https://www.aveooncology.com/aveo-oncology-an-lg-chem-company-announces-acceptance-of-late-breaking-oral-presentation-of-tinivo-2-results-at-esmo-2024/.